Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases

被引：36

作者：

Ventrice, Pasquale ^{[1
,2
]}

Leporini, Christian ^{[1
,2
]}

Aloe, Jose' Francisco ^{[3
]}

Greco, Ettore ^{[4
]}

Leuzzi, Giacomo ^{[1
,2
]}

Marrazzo, Giuseppina ^{[1
,2
]}

Scorcia, Giovanni Battista ^{[5
]}

Bruzzichesi, Donatella ^{[5
]}

Nicola, Varano ^{[5
]}

Scorcia, Vincenzo ^{[5
]}

机构：

[1] Univ Catanzaro, Sch Med, Dept Hlth Sci, Catanzaro, Italy

[2] Univ Hosp Mater Domini, Pharmacovigilances Ctr Calabria Reg, Dept Hlth Sci, Catanzaro, Italy

[3] Giovanni Paolo II Hosp, Pharm Unit, Lamezia Terme, Italy

[4] Giovanni Paolo II Hosp, Oncol Unit, Lamezia Terme, Italy

[5] Magna Graecia Univ Catanzaro, Dept Ophthalmol, Catanzaro, Italy

来源：

JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS | 2013年 / 4卷 / 05期

关键词：

Adverse drug reactions; aflibercept; age-related macular degeneration; bevacizumab; choroidal neovascularization; ranibizumab;

D O I：

10.4103/0976-500X.120947

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Macular degeneration is the leading cause of blindness in developed countries. In the treatment of neovascular age-related macular degeneration, vascular endothelial growth factor (VEGF) has emerged as a key target for therapy. The intravitreal injection of anti-VEGF drugs has been widely employed to reduce the disease progression and improve the visual outcomes of the affected patients. However, each intravitreal inoculation poses a risk of several complications as infection, inflammation, endophthalmitis, intraocular inflammation, increase of intraocular pressure and vitreous hemorrhage. This short review evaluates the efficacy and the incidence of adverse drug reactions related to intravitreal administration of the main anti-VEGF drugs actually available: Bevacizumab, ranibizumab and aflibercept.

引用

页码：S38 / S42

页数：5

共 37 条

[1] Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy [J].

Avery, Robert L. ;

Pearlman, Joel ;

Pieramici, Dante J. ;

Rabena, Melvin D. ;

Castellarin, Alessandro A. ;

Nasir, Ma'an A. ;

Giust, Matthew J. ;

Wendel, Robert ;

Patel, Arun .

OPHTHALMOLOGY, 2006, 113 (10) :1695-1705

[2] Angiogenesis in cancer and other diseases [J].

Carmeliet, P ;

Jain, RK .

NATURE, 2000, 407 (6801) :249-257

[3] Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration [J].

Chakravarthy, Usha ;

Harding, Simon P. ;

Rogers, Chris A. ;

Downes, Susan M. ;

Lotery, Andrew J. ;

Wordsworth, Sarah ;

Reeves, Barnaby C. .

OPHTHALMOLOGY, 2012, 119 (07) :1399-1411

[4] Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization - Six-month results of a prospective pilot study [J].

Chan, Wai-Man ;

Lai, Timothy Y. Y. ;

Liu, David T. L. ;

Lam, Dennis S. C. .

OPHTHALMOLOGY, 2007, 114 (12) :2190-2196

[5] Lucentis (R) using Visudyne (R) study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration [J].

Chen, Eric ;

Brown, David M. ;

Wong, Tien P. ;

Benz, Matthew S. ;

Kegley, Eric ;

Cox, Joel ;

Fish, Richard H. ;

Kim, Rosa Y. .

CLINICAL OPHTHALMOLOGY, 2010, 4 :1073-1079

[6] Age related macular degeneration [J].

Chopdar, A ;

Chakravarthy, U ;

Verma, D .

BRITISH MEDICAL JOURNAL, 2003, 326 (7387) :485-488

[7] Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA study): Results of a phase 1 dose-escalation study [J].

Costa, Rogerio A. ;

Jorge, Rodrigo ;

Calucci, Daniela ;

Cardillo, Jose A. ;

Melo, Luiz A. S., Jr. ;

Scott, Ingrid U. .

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2006, 47 (10) :4569-4578

[8] Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy [J].

Dvorak, HF .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4368-4380

[9] Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer [J].

Ferrara, N ;

Hillan, KJ ;

Gerber, HP ;

Novotny, W .

NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (05) :391-400

[10] The biology of VEGF and its receptors [J].

Ferrara, N ;

Gerber, HP ;

LeCouter, J .

NATURE MEDICINE, 2003, 9 (06) :669-676

← 1 2 3 4 →